Algernon Pharmaceuticals Provides Update on COVID-19 Phase 2b Final Study Data
On February 17, 2021, Algernon Pharmaceuticals Inc. (CSE: AGN, OTCQB: AGNPF) updated on its Phase 2b/3 study of Ifenprodil for COVID-19. A fire at a Romanian hospital site delayed the site audit, but the company has completed the source data audit for all patients. The database will be locked for analysis on March 5, and results will be shared soon after. Notably, many patients received imaging scans, aiding the exploration of Ifenprodil's potential in reducing post-COVID lung scarring, although the data will be reviewed separately to avoid further delays.
- Completion of the source data audit for all patients in the Ifenprodil study.
- Final data analysis set to be locked on March 5, leading to timely market updates.
- Delay in the audit process due to a fire at the Romanian hospital.
VANCOUVER, British Columbia, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to provide an update on the final data set of the Phase 2b part of the Phase 2b/3 COVID-19 Ifenprodil study.
The Company reports that due to a fire at the Romanian Hospital site, there was a delay in completing the site audit as planned. However the Company is pleased to report that the source data audit from all sites and for all patients is now complete. The database will be locked for analysis on March 5th and the Company will update the market on the final data release shortly thereafter.
Additionally, the Company has confirmed that a significant number of patients in the study did receive some form of an imaging scan as part of their release protocol from the hospital. While Algernon believes the data may be helpful in establishing Ifenprodil’s possible role in reducing post COVID infection lung scarring, in order to ensure the final data process is not delayed further, the data will be reviewed as supplemental, at a later date.
About Algernon Pharmaceuticals Inc.
Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.
CONTACT INFORMATION
Christopher J. Moreau
CEO
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701
info@algernonpharmaceuticals.com
investors@algernonpharmaceuticals.com
www.algernonpharmaceuticals.com.
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
FAQ
What is the current status of the Ifenprodil COVID-19 study by Algernon Pharmaceuticals?
How did the fire at the Romanian hospital affect the Ifenprodil study?
When will the results of the Ifenprodil study be released?
What role might Ifenprodil play in post-COVID recovery according to Algernon Pharmaceuticals?
What is the significance of the imaging scans received by patients in the Ifenprodil study?
